Proquility Private Wealth Partners LLC Sells 4,244 Shares of Johnson & Johnson (NYSE:JNJ)

Proquility Private Wealth Partners LLC cut its position in Johnson & Johnson (NYSE:JNJ) by 57.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,182 shares of the company’s stock after selling 4,244 shares during the quarter. Proquility Private Wealth Partners LLC’s holdings in Johnson & Johnson were worth $460,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Tide Cove Capital Partners LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth $2,448,000. Octavia Wealth Advisors LLC raised its stake in shares of Johnson & Johnson by 3.3% during the 4th quarter. Octavia Wealth Advisors LLC now owns 13,885 shares of the company’s stock valued at $2,008,000 after purchasing an additional 447 shares during the period. Commons Capital LLC boosted its stake in Johnson & Johnson by 4.8% in the 4th quarter. Commons Capital LLC now owns 2,037 shares of the company’s stock worth $295,000 after purchasing an additional 93 shares during the period. Fort Washington Investment Advisors Inc. OH grew its holdings in Johnson & Johnson by 4.1% during the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 1,702,574 shares of the company’s stock valued at $246,226,000 after buying an additional 67,629 shares in the last quarter. Finally, LifePlan Financial LLC increased its position in shares of Johnson & Johnson by 238.4% during the fourth quarter. LifePlan Financial LLC now owns 4,227 shares of the company’s stock valued at $611,000 after buying an additional 2,978 shares during the period. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.1 %

Shares of NYSE:JNJ opened at $146.76 on Friday. The stock has a market capitalization of $353.34 billion, a P/E ratio of 22.07, a price-to-earnings-growth ratio of 2.45 and a beta of 0.51. The stock’s 50-day moving average price is $147.99 and its 200-day moving average price is $155.98. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22,438,500 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.29 EPS. On average, equities analysts anticipate that Johnson & Johnson will post 10.56 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.38%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts recently commented on JNJ shares. Citigroup reduced their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Barclays decreased their price target on shares of Johnson & Johnson from $160.00 to $159.00 and set an “equal weight” rating on the stock in a report on Tuesday. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Bank of America lowered their price target on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a report on Thursday. Finally, Morgan Stanley cut their price objective on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a report on Thursday. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $170.06.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.